

placed in Schedule IV. In Federal Register notices on May 9 and May 10, 1973, we proposed the precise scheduling recommended by HEW.

No objections were received from such major manufacturers of the anorectics proposed for Schedule III as the Upjohn Company (Didrex), Warner/Chilcott (Pre-Sate), USV Pharmaceutical (Voranyl), Sandoz Pharmaceuticals (Sanorex), or Ayerst Laboratories (Plegine). No objection to the proposed scheduling of fenfluramine (Pondimin) in Schedule IV was received from the A. H. Robins Company.

Two major manufacturers filed objections:

1. Merrell-National Laboratories requested a hearing on the scheduling of its product, Tenuate, in Schedule III.

2. Pennwalt Corporation, on the scheduling of its product, Ionamin, in Schedule III.

The Merrell and Pennwalt hearing requests presented a grave policy issue involving fundamental fairness. All but these two companies had agreed to the HEW-DEA scheduling proposals. If the products